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ABSTRACT
Introduction: Glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) are a relatively new class of
injectable drugs used in the treatment of type 2
diabetes (T2D). This retrospective database
study evaluated real-world treatment patterns
of T2D patients initiating GLP-1 RAs in Belgium
(BE), France (FR), Germany (DE), The
Netherlands (NL) and Sweden (SE).
Methods: Adult T2D patients initiating
exenatide twice daily (exBID), exenatide once
weekly (exQW), liraglutide (LIRA) or
lixisenatide (LIXI) during 2013 were identified
using the QuintilesIMS (QuintilesIMS, Durham,
NC, and Danbury, CT, USA) longitudinal retail
pharmacy databases (LRx; BE/FR/DE/NL) and
national health register data (SE). Therapy
initiation date was termed ‘index date.’
Eligible patients had C180-day pre- and
variable follow-up (minimum C360 days
post-index). Baseline patient and treatment
characteristics were assessed. Treatment
modification and persistence were evaluated
over the 1-year follow-up. Kaplan-Meier (KM)
survival curves evaluated stopping of the index
therapy (first of discontinuation or switch) over
the available follow-up.
Results: A total of 4339 exBID, 1499 exQW,
20,955 LIRA and 1751 LIXI patients were
included in the analysis (45.1–61.9% female;
mean age range 57.1–62.9 years). Mean
follow-up ranged from 17.7 to 30.7 months.
Across countries/databases, the proportion
experiencing a treatment modification at
1-year ranged from 84.1 to 93.8% for exBID,
53.3–73.4% for exQW and 59.5–80.5% for LIRA
patients. The proportion of LIXI patients with
treatment modification was 55.0% in Belgium
(N = 20) and 96.9% in Germany (LIXI taken off
the German market in April 2014). In KM
analyses, LIRA patients had the lowest
proportion stopping therapy, while exBID
patients had the highest proportion stopping
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therapy, across databases, with the exception of
LIXI patents.
Conclusion: Treatment patterns varied among
GLP-1 RA patients, and persistence was
generally highest among LIRA and lowest
among exBID across countries. Longer term
data would be useful, given the recent
approval of several GLP-1 RA
therapies.Funding: Eli Lilly and Co.,
Indianapolis, IN, USA.
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INTRODUCTION
The International Diabetes Federation estimates
that in 2015 there were 59.8 million adults with
diabetes in Europe (EU), representing 9.1% of
adults, including 23.5 million cases that are
undiagnosed [1]. Up to 91% of adults with
diabetes in high-income countries have type 2
diabetes (T2D) [1]. This has substantial cost
implications to healthcare systems and society,
with approximately 12% of global health
expenditures spent on diabetes in 2015 [1].
Most patients with T2D will require drug
therapy with an antihyperglycemic agent to
help in regulating glucose control through
reductions in hepatic glucose production,
stimulation of insulin release, regulation of
insulin and glucagon secretion, or
improvement of insulin sensitivity [2].
Metformin, an oral antihyperglycemic
medication (OAM), is recommended for most
as the optimal drug for initial monotherapy [2].
Over time, combination therapy is needed, and
the updated 2015 joint position statement
released by the American Diabetes Association
(ADA) and European Association for the Study
of Diabetes (EASD) recommends one of six
treatment classes combined with metformin:
an OAM including a sulfonylurea,
thiazolidinediones (TZD), dipeptidyl
peptidase-4 (DPP-4) inhibitor or
sodium–glucose cotransporter 2 (SGLT2)
inhibitor, or an injectable antihyperglycemic
agent including a glucagon-like peptide-1
receptor agonist (GLP-1 RA) or basal insulin
[2]. Progressive beta-cell dysfunction prevents
many patients from maintaining adequate
glycemic control with OAMs over the long
term, and many patients will eventually also
require injectable glucose-lowering therapies
[3, 4].
Glucagon-like peptide-1 receptor agonists are
a relatively new class of injectable drugs used in
the treatment of T2D. GLP-1 RAs mimic
endogenous GLP-1, stimulating insulin release
from the pancreas, suppressing glucagon
secretion, slowing gastric emptying and
increasing satiety [2]. There are several GLP-1
RAs that have been approved by the European
Medicines Agency (EMA). Exenatide twice-daily
(BID; Byetta, AstraZeneca) was first in class and
approved by the EMA in 2006, followed by
liraglutide (Victoza, Novo Nordisk) in 2009
and exenatide once weekly (Bydureon,
AstraZeneca) in 2011 [5–7]. GLP-1 RAs recently
approved in Europe include lixisenatide
(Lyxumia, Sanofi) in February 2013 (not yet
approved by the Food and Drug Administration
in the USA), albiglutide (Eperzan,
GlaxoSmithKline) in April 2014 and
dulaglutide (Trulicity, Eli Lilly) in December
2014 [8–10].
Glucagon-like peptide-1 receptor agonists
vary in the magnitude of their effect in
reducing HbA1c, effect on weight loss and
adverse event profiles. Additionally, dosing
schedules (daily dose, injection frequencies,
etc.) are variable. For example, the initial dose
of exenatide BID is 5 lg injected under the skin
(subcutaneously) twice daily, within 60 min
before the two main meals of the day for at
least 1 month [5]. The dose can be increased to
10 lg twice daily thereafter. Liraglutide is
administered once daily independent of meals
and should be initiated with a dose of 0.6 mg for
the first week, followed by a dose increase to
1.2 mg [6]. If the 1.2 mg dose does not result in
acceptable glycemic control, the dose may be
increased to 1.8 mg after at least 1 week, as some
patients are expected to benefit from the
increase in dose. Lixisenatide is also
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administered once per day, within an hour of
any meal, with a starting dose in the 2 weeks
following initiation of 10 lg and with a
subsequent fixed maintenance dose of 20 lg
[8]. Exenatide once weekly (exenatide QW) is
administered independent of meals at a dose of
2.0 mg [7]. Albiglutide and dulaglutide are also
administered once per week, independent of
meals [9, 10]. While the ADA/EASD recommend
GLP-1 RA therapy as early as second-line
therapy, some EU healthcare authorities, such
as those in the UK, The Netherlands and
Belgium, generally recommend GLP-1 RAs as a
third-line therapy, in some cases as a condition
of reimbursement and often restricted to certain
populations (obese, unable to use insulin, etc.)
[11–13].
Only a few prior studies have compared
treatment patterns or variable dosing among
exenatide BID, liraglutide and/or exenatide QW
in the EU and in the US [14–20]. Little is known
about current real-world treatment patterns
among GLP-1 RA therapy users given the
recent introduction of several GLP-1 RA
therapies or average patient dosing given
variability in dosing for exenatide BID and
liraglutide. The primary objective of this
analysis was to evaluate current persistence
and treatment patterns among patients with
T2D newly initiating the GLP-1 RA therapy class
(exenatide BID, exenatide QW, liraglutide or
lixisenatide; the only approved GLP-1 RAs
during the selection window of this study)
using available databases containing
prescription data in Belgium, France, Germany
and The Netherlands and diagnoses and
prescription data in Sweden. Secondary
objectives included evaluating the average
daily dose (ADD) of the GLP-1 RA therapy.
METHODS
A retrospective cohort analysis was conducted
using five available databases in five European
countries of interest: Belgium, France,
Germany, The Netherlands and Sweden. Data
from these countries were utilized in a prior
analysis by the authors, and these countries
were selected to provide a broad representation
of several European countries [16]. Research
ethics approval was received from the regional
Ethics Review Board in Stockholm to conduct
the Swedish analysis. Ethics approval was not
required in the other countries.
Data Sources
Retail Pharmacy (LRx)
The QuintilesIMS (QuintileIMS, Durham, NC,
and Danbury, CT, USA) longitudinal retail
pharmacy data (henceforth referred to as LRx)
were used in Belgium, France, Germany and The
Netherlands. LRx contains prescription data
[EphMRA Anatomical Classification (ATC)
code, quantity dispensed, prescriber specialty,
etc.] and limited demographic data [e.g., age
(unavailable for analysis in Belgium) and gender
(partially available in Germany and unavailable
in France)]. The representativeness of the
databases based upon current population and
pharmacy coverage from 2013 to 2015 is as
follows: *33% Belgium (33% of all
prescriptions), 32% France (32% of all
pharmacies), *60% Germany (60% of German
statutory health insurance prescriptions) and
75% The Netherlands (75% of all prescriptions).
Pharmacy coverage is as follows: [1600
pharmacies in Belgium, 7052 pharmacies in
France, 12,300 pharmacies in Germany and
2400 pharmacies in The Netherlands and is
representative of both large and small cities and
most if not all regions.
Sweden
Patient-level de-identified national data from
three registries were linked for the analysis in
Sweden: the Drug Register, the Patient Register
and the Mortality Register. The Swedish Drug
Register provides national, patient level data on
all prescription drugs dispensed at all
pharmacies from the Swedish National
Pharmacy Corp. [World Health Organization
(WHO) ATC code]. The Swedish Patient Register
includes clinical data—i.e., medical diagnosis
codes [International Statistical Classification of
Diseases (ICD) ICD-10 format], but not
laboratory values—as well as information on
healthcare utilization and associated costs from
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both in- and out-patient specialist care
(unavailable from the primary care setting).
The Swedish Mortality Register was used to
identify patient death and provide full visibility
into patient follow-up.
Patient Selection
Patients were first identified based on a
prescription for the therapy of interest
(exenatide BID, exenatide QW, liraglutide or
lixisenatide) within the selection window of 1
January 2013 to 31 December 2013. Important
to note, liraglutide (Saxenda, Novo Nordisk),
indicated for weight management for adults
who are obese or overweight and approved in
the EU in March 2015, was not included in the
study [21]. The first prescription for a therapy of
interest within the selection window was
termed the index drug, and the date was
termed the index date. Patients were followed
through the end of continuous eligibility [CE,
i.e., visibility (composite of patient activity in
the database and stability of pharmacy
reporting in LRx; patient activity without
death in Sweden)] up to the end of the
available study data (Belgium, Germany, The
Netherlands: 31 October 2015; France: 31
August 2015; Sweden: 31 December 2014).
Adult patients (C18 years on the index date)
were identified as eligible if they met the
following inclusion/exclusion criteria: (1)
evidence of T2D (and no evidence of T1D) in
the 180-day pre-index period; (2) C180 days CE
pre-index (the 6-month pre-index or baseline
period) and (3) C360 days CE post-index
(minimum 1-year post-index or follow-up
period) within the database; (4) naı¨ve to the
GLP-1 RA therapy class with no prescription for
any GLP-1 RA in the 180-day pre-index period;
(5) not initiating any other
injectable antihyperglycemic therapy on the
index date other than the index therapy; (6)
non-missing age or gender [exceptions for
Belgium (age unavailable for analysis) and
Germany and France (gender partially
available and unavailable, respectively)].
For the LRx analyses, the requirement for
evidence of T2D (and no evidence of T1D) was
determined by C1 OAM class used in the
pre-index period, as only prescription data
were available (and no diagnoses). In Sweden,
where diagnoses were available, evidence of
T2D was required as either: (1) diagnosis codes
of diabetes (ICD-10 CM: E10–E14) in the 180
days pre-index up to 60 days post-index or (2) at
least C1 OAM class and no diagnosis of
polycystic ovarian syndrome (ICD-10 CM:
E28.2) in the pre-index period. Patients were
excluded if they had evidence of T1D, which
was evaluated among patients with a diagnosis
of E10 in the pre-index period, and identified if
all of the following criteria were met: (1) no E11
diagnosis (T2D), (2) no OAM use, (3) insulin use
in the pre-index period and (4) 40 years of age
or younger at the first E10 diagnosis. Patients
were also excluded if they had pregnancy
diagnoses (ICD-10 CM: O00–O9A0) in the
pre-index period.
Measures and Analysis
Baseline demographic characteristics (age and
gender where available) and prescriber specialty
associated with the index therapy were assessed
as well as non-index antihyperglycemic therapy
classes used in the pre-index period.
Concomitant antihyperglycemic therapy use
on the index date was also assessed. A
non-index antihyperglycemic therapy class
was defined as concomitant if the time
between a prescription for a therapy class in
the pre- and post-index period was less than
120 days, with overlap on the index date, or if
the therapy class was filled on the index date.
Missing prescription quantity data were
present in The Netherlands only, but not for
the other databases. For the analysis in The
Netherlands, patients with missing prescription
quantity data were excluded from the
subsequent ADD and treatment modification
analyses [5 liraglutide patients (0.4% of the total
liraglutide patients)].
Experience of a first treatment modification
was assessed during the 1-year post-index
period. Treatment modifications included
discontinuation, switch, augmentation,
off-label up-titration and off-label
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down-titration of the index GLP-1 therapy,
assessed following previously published
methods [15, 16]. A detailed description of the
methods and definitions utilized may be found
in our prior publication [16]. Discontinuation
was defined as a gap in a series of successive
index therapy prescriptions C29 the expected
duration of the first prescription. Switching was
defined as a new non-index antihyperglycemic
prescription within 30 days before or after
discontinuation of the patient’s index
treatment, while augmentation was defined as
a new non-index antihyperglycemic
prescription, started more than 30 days before
the end of follow-up or the index
discontinuation date. Off-label up-titration was
identified as any dose increase outside of label
recommendations (daily dose [20 lg for
exenatide BID; two consecutive prescriptions
with daily dose [1.8 mg for liraglutide).
Off-label down-titration was defined as two
consecutive prescriptions with doses lower
than the index dose. On-label up-titration was
assessed as a separate outcome, defined as any
dose increase based on label recommendations
(two consecutive prescriptions with ADD of
20 lg for exenatide BID; two consecutive
prescriptions with ADD C1.2 mg up to 1.8 mg
for liraglutide).
Persistence (i.e., continuation of the index
therapy) was evaluated during the 1-year
post-index period. Patients were considered
persistent until evidence of discontinuation or
switch. A stop outcome was defined as the
occurrence of either discontinuation or switch
(whichever came first).
The ADD of the index therapy was assessed
for all patients while persistent. Daily dose was
calculated by dividing the total amount or units
of drug prescribed by the number of days
between two consecutive prescriptions. ADD
was evaluated by calendar month intervals for
patients with an index therapy prescription
within that month. Average ADDs over
calendar months were summarized to provide
both a yearly ADD and an overall ADD. An
average weekly dose (AWD) was calculated for
exenatide QW by multiplying the daily dose by
7. For yearly and overall ADD/AWD
calculations, calendar months with fewer than
30 patients were trimmed. Further details on
data cleaning for the ADD calculations can be
found in our prior publication [16].
Descriptive summary statistics were used to
describe frequency and percentage distributions
for categorical variables while continuous and
count variables were described using the mean,
standard deviation and median. Time to stop
the index therapy over the variable follow-up
was assessed using Kaplan-Meier (KM) analysis.
No formal statistical tests were performed to
compare outcomes between index therapy
cohorts. However, for the KM analysis, the
log-rank test was conducted to examine
differences among all included index therapies
for each country/data set. Statistical and
descriptive analyses were performed using SAS
version 9.2 or higher (Cary, NC, USA).
RESULTS
Patient Sample
After application of the inclusion/exclusion
criteria, the final sample consisted of 4339
exenatide BID patients (80 Belgium; 1884
France; 2261 Germany; 44 The Netherlands;
70 Sweden), 1499 exenatide QW patients (1035
Germany; 122 The Netherlands; 342 Sweden),
20,955 liraglutide patients (666 Belgium; 8606
France; 6916 Germany; 1324 The Netherlands;
3443 Sweden) and 1751 lixisenatide patients (20
Belgium; 1731 Germany).
Please see Table S1 in the supplementary
material for baseline demographic
characteristics and antihyperglycemic therapy
use of the study sample. Across index therapy
cohorts and databases, patients were mostly in
the 50–64 age group (41.8–59.1%) with mean
age ranging from 57.1 to 62.9 years.
Approximately half or more of patients were
female (45.1–61.4%). LRx patients had mean
follow-up of approximately 2 years or more
(20.0–30.7 months); mean follow-up in
Sweden was shorter at 18 months.
On average, patients used 1.6–3.0
antihyperglycemic therapy classes in the
180-day pre-index period (with a median of 2
classes for most index therapy cohorts).
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Biguanides (i.e., metformin) were the most
common antihyperglycemic therapy class used
in the 180-day pre-index period for all cohorts
across databases (54.0–88.5%). Sulfonylureas
were the second most commonly used
antidiabetic class in the pre-index period in
Belgium, France and The Netherlands
(43.7–74.5%). In Germany, the second most
commonly used antidiabetic class was DPP-4/
biguanides for exenatide QW (30.0%) and
liraglutide (21.9%) patients, while long-acting
insulin was most commonly used for exenatide
BID (26.2%) and lixisenatide (39.2%) patients.
In Sweden, DPP-4s were the second most
commonly used antidiabetic class in the
pre-index period for exenatide QW (28.6%)
patients, while intermediate-acting insulin was
second most commonly used for exenatide BID
(28.5%) and liraglutide (22.9%) patients.
Mean number of concomitant antidiabetic
therapy classes used on the index date ranged
from 1.0 to 2.0 classes. Median number of
co-occurring antidiabetic therapy classes used
on the index date varied, and all index therapy
cohorts in Germany and Sweden had a median
of 1, while most index therapy cohorts in
Belgium, France and The Netherlands had a
median of 2. Across countries/data sets,
biguanides were most frequently co-occurring
on the index date and used by more than half
(53.5–83.9%). Sulfonylureas were the second
most commonly co-occurring antidiabetic
therapies on the index date for most index
therapy cohorts in Belgium, France and The
Netherlands (45.0–66.2%). In Germany and
Sweden, after biguanides, most index therapy
cohorts did not have a co-occurring antidiabetic
therapy on the index date (15.7–24.5%).
For the overall GLP-1 RA cohorts across
countries/databases, a general practitioner (GP)
was the most common prescribing physician
specialty associated with the index prescription
in Belgium (47.5%), France (72.8%) and Sweden
(50.1%). An internist was most common in
Germany (52.7%) and The Netherlands (71.1%).
For the most part, specialty did not vary by
index therapy cohort, with the exception of
Germany, where the proportion of patients
with an internist and proportion with a GP
were equal for exenatide QW patients (46.3%
and 46.2%, respectively).
Treatment Patterns
At 1 year post-index, the proportion persistent
for liraglutide patients ranged from 29.0%
(Belgium) to 60.8% (The Netherlands) and for
exenatide BID patients ranged from 17.5%
(Belgium) to 44.4% (France) (Table 1). The
proportion persistent for exenatide QW ranged
from 32.8% (Germany) to 50.8% (The
Netherlands). The proportion persistent for
lixisenatide was 50.0% in Belgium and 4.2% in
Germany (lixisenatide was taken off the market
in April 2014 in Germany) [22].
KM results for time to stop (discontinuation
or switch) over the variable follow-up by index
therapy cohort can be found in Fig. 1a–d. Across
countries/data sets, for most time points, the
proportion stopping was lowest among
liraglutide patients and highest among
exenatide BID patients at all time points, again
with the exception of lixisenatide patients in
Belgium and Germany. Median time to stop
ranged from 111 days (Belgium) to 273 days
(France) for exenatide BID, 193 days (Belgium)
to 566 days (The Netherlands) for liraglutide
and 164 days (Germany) to 385 days (The
Netherlands) for exenatide QW, and for
lixisenatide, it was 347 days in Belgium and
129 days in Germany. Across data
sets/countries, the log-rank test resulted in a
p value \0.001 between the available index
therapies.
Treatment modifications at 1 year post-index
can be found in Table 1 by index therapy
cohort. Most exenatide BID patients
experienced treatment modification, ranging
from 84.1% (The Netherlands) to 93.8%
(Belgium). More than half of liraglutide
patients experienced treatment modification,
ranging from 59.5% (Sweden) to 80.5%
(Belgium). Proportion of exenatide QW
patients with treatment modification ranged
from 53.3% (The Netherlands) to 73.4%
(Germany). Proportion of lixisenatide patients
with treatment modification was 55.0% in
Belgium and 96.9% in Germany. For most
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cohorts, among patients with a treatment
modification, discontinuation was the most
common first treatment modification (37.2–
81.8%).
Average Daily Dose
ADD by calendar year (year of prescription) and
overall (over the available follow-up period) is
reported in Table 2. Mean (SD) overall ADD for
exenatide BID was on the higher end of the
approved doses and was 18.55 (1.24) lg in
Germany and 18.69 (0.74) lg in France. Mean
yearly ADD for exenatide BID was stable in
France and increased in Germany. Overall ADD
for liraglutide was generally in the middle of the
indicated maintenance doses and ranged from
1.41 (0.12) mg in Belgium to 1.68 (0.14) mg in
the Netherlands. Mean yearly ADD for
liraglutide increased by year across
countries/data sets. Overall ADD for exenatide
QW ranged from 0.29 (0.01) mg in Germany to
0.30 (0.01) mg in The Netherlands, with a
respective average weekly dose of 2.03 (0.07)
mg to 2.10 (0.09) mg, close to the expected
average weekly dose. Mean yearly ADD for
exenatide QW was stable by year across
countries/data sets. Mean (SD) overall ADD for
lixisenatide was 20.11 (2.33) lg in Germany,
close to the approved maintenance dose. Mean
yearly ADD increased for lixisenatide from 2013
to 2014 in Germany.
DISCUSSION
In this real-world analysis in five European
countries, treatment patterns varied among
new initiators of GLP-1 RAs. For the most part,
we observed that exenatide BID patients were
most likely to modify or stop therapy, while
liraglutide patients were most persistent. We
found that treatment modification results for
exenatide QW relative to liraglutide varied by
data set (similar between exenatide QW and
liraglutide patients in Germany and Sweden
and lower for exenatide QW patients compared
to liraglutide patients in The Netherlands). In
Belgium, proportion with a first treatment
modification at 1 year post-index was lower
for lixisenatide patients compared to liraglutide
patients (55.0% and 80.5%); however, the
lixisenatide sample was limited (N = 20). The
overall ADD of GLP-1 RAs was generally within
the label-indicated ranges. The overall ADD for
liraglutide was generally in the middle of the
indicated maintenance doses (1.2 or 1.8 mg
following the second week) and increased by
year from initiation. Longer term data would be
useful to further clarify practice patterns among
the GLP-1s, given the recent launch of several
new GLP-1 RAs in the EU. While our study is the
first to examine treatment patterns and dosing
for lixisenatide specifically, additional research
is needed to more broadly understand its use
outside of Belgium and Germany.
Our findings mirror those in several other
studies that conclude that treatment patterns
vary among GLP-1 RA patients [15, 16]. Miller
et al., using a German EMR database
(2009–2010), found that time to treatment
modification was shorter for exenatide BID
patients compared to liraglutide patients,
similar to our findings of more exenatide BID
patients experiencing treatment modification at
1 year post-index compared to liraglutide
patients across countries/databases [15]. A
prior analysis conducted by the authors of this
study, using various data sources across several
European countries (including some of the
same databases/countries used in the current
analysis), found that the proportion of patients
that experienced a treatment modification and
that stopped the index therapy by 180 days
post-index were highest among exenatide BID
patients compared to liraglutide or exenatide
QW patients [16]. Similar to our analysis, the
proportion persistent at 180 days was highest
for liraglutide compared to exenatide QW in
The Netherlands LRx, Germany LRx and
Sweden. Fewer exenatide QW patients
experienced treatment modification compared
to liraglutide patients in Sweden, while
proportions were more similar in The
Netherlands LRx and Germany LRx. In our
analysis, treatment modification at 1 year
post-index was similar between exenatide QW
and liraglutide patients in Germany and
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Sweden, but lower for exenatide QW patients
compared to liraglutide patients in The
Netherlands. Differences in study findings may
be related to different time periods as the prior
analysis was conducted soon after exenatide
QW’s launch, as well as different follow-up
times.
Average daily dose of GLP-1 RAs was
generally within the label-indicated ranges,
similar to findings from other European
studies. Using the LRx database in Germany,
Fuchs et al. found a mean daily dose of 1.42 mg
including extreme values for liraglutide
(2009–10) and a mean daily dose of 1.29 mg
excluding extreme values, both lower than the
1.55 mg observed in our study [14]. Differences
may in part be related to varying methods
(trimming vs. removing extreme values). Miller
et al. evaluated ADD for exenatide BID and
liraglutide (2009–10) using EMR data in
Germany [15]. Mean ADD was 16.7 lg for
exenatide BID and 1.43 mg for liraglutide,
while in our Germany LRx analysis, we found
higher mean ADD (18.55 lg and 1.55 mg,
respectively). Compared to the prior analysis
conducted by the authors in an earlier study
period (2010–2013) and the same
databases/countries, we observed in our
current analysis that overall ADD has
increased over time using a more recent study
period (2013–2015) [16]. For example, overall
ADD for exenatide BID increased from 17.70 lg
in the prior analysis to 18.55 lg in the current
study in Germany. This trend was also observed
for overall ADD for liraglutide in Belgium
(1.30–1.41 mg), Germany (1.40–1.55 mg), The
Netherlands (1.61–1.68 mg) and Sweden
(1.52–1.60 mg). The observed increase in ADD
over time may suggest that prescribing
physicians are more comfortable up-titrating
exenatide BID and liraglutide per label as they
become more familiar with GLP-1 RAs. As a
note, we also observed fewer initiators of
exenatide BID compared to our prior analysis,
suggesting a potential preference of prescribing
physicians for use of other GLP-1 RAs such as
liraglutide or exenatide QW, which may be
related to their more convenient dosing
schedules. Additionally, it may be important
to understand the dosing associated with GLP-1
RA therapy from the payer perspective. Changes
in dosing may result in a less
predictable budgetary impact as compared to
regimens with fixed dosing.
There are a few limitations to note related to
typical database research. Patients included in
the LRx databases may not be fully
representative of all patients in the respective
country, as data are collected only from
participating pharmacies. LRx lacks visibility
to any prescriptions purchased outside of the
participating pharmacies. The lack of medical
diagnosis codes in LRx and unavailability of
medical diagnosis codes from the primary care
setting in Sweden made it difficult to confirm
the presence/absence of T1D and/or T2D. LRx
lacks the ability to identify patient mortality.
Additionally, while a prescription may be
prescribed or filled, real-world consumption
patterns may differ. Results from retrospective
database studies must be interpreted with
caution, and in context with results from
other studies, because they can only establish
associations and not cause-and-effect
relationships. We were unable to investigate
reasons for treatment modifications (lack of
effectiveness, adverse events, etc.) as the data
lack this clinical detail. Our sample may be
biased toward a healthier population because of
our continuous enrollment requirements,
which were necessary to ensure adequate
visibility into the patients’ clinical history; this
may be less of an issue among patients with
chronic diseases, such as diabetes. Further,
small sample sizes [particularly for exenatide
BID in Belgium (N = 80), The Netherlands
(N = 44) and Sweden (N = 70) and lixisenatide
patients in Belgium (N = 20)] for some
cohorts/databases limited comparisons.
Lixisenatide was taken off the market in
Germany in April 2014, impacting observed
treatment patterns.
Fig. 1 Kaplan-Meier analyses for time to stop: a exBID;
b LIRA; c exQW; d LIXI. BE Belgium, exBID exenatide
twice daily, exQW exenatide once weekly, FR France; DE
Germany, LIRA liraglutide, LIXI lixisenatide, NL The
Netherlands, SE Sweden
b
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CONCLUSION
The GLP-1 RA class has grown in the last decade
with several agents available for use in the US
and Europe and several more in development
[23]. This study is one of the first to
comprehensively examine recent treatment
patterns and ADD of GLP-1 RA therapies,
including lixisenatide, across various EU
countries and data sets. In this real-world
analysis, treatment patterns varied among
GLP-1 RA patients in the sample of European
countries considered in this study. ADD was
within indicated label ranges. Longer term data
would be useful to further understand
treatment patterns associated with GLP-1 RAs,
given the recent approval of several GLP-1 RA
therapies and the observed changes in GLP-1 RA
treatment patterns and dosing over time.
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